A recent string of bigger-ticket acquisitions, including those of Mirati and Point, may serve as fodder to analysts who expect an uptick in biopharma deals.This summer, large biotechnology deals took a vacation.In the three-month period from July through September, just six acquisitions worth at least $50 million were announced, according to data compiled by BioPharma […]
